FourFour two reveals that the name of the new drug is ‘Medivac’.
However, the article reveals that it is not a drug that has been developed by the pharmaceutical industry.
It is a name chosen by a pharmaceutical company.
This is in keeping with a trend of pharmaceutical companies not choosing names which are the result of a rigorous research and development process, but rather naming the product after an existing product or a brand that has had a long run in the market.
One of the reasons for this is that, for example, pharmaceutical companies often choose names to describe products they want to sell, as well as their brand names.
As the name Medivac is not one of these, it may not be appropriate to call it a generic drug, and there are no plans for the name to be rebranded in the near future.
Medivacs, a generic name for a drug, is usually used for generic drugs, and generic names are generally more accurate for generic medicines.
As for the company that created Medivacl, it is a UK-based company called Valeant Pharmaceuticals.
Valeant has also released a press release stating that Medivax will be developed by a UK company called AstraZeneca.
This means that, if the company does not change its name, it will still be known as Valeant.
However, the name ‘Medix’ appears in a number of documents from the company’s website.
This name, which was suggested by a patient who saw it on the cover of a UK newspaper, was not approved by the Food and Drug Administration (FDA) for a generic medication, and therefore is not the name the company is using.
So, the company behind the new generic drug is AstraMedica, and it is still a British company.
The only difference is that the company will not be using the word ‘generic’ in its name.
Why is this newsworthy?
The article mentions the name “Medix”, which was first suggested by the patient who suggested the name.
However, this name was not endorsed by the FDA and is not approved for a generics medication.
When the company created the generic drug Medivacc, it did not know what the name was.
This was because it had not seen the FDA’s approval for a product which is not yet ready for market.
What is the company planning to do with the Medivoc?
As previously mentioned, the product name is still in use.
However the company has already started a marketing campaign which will be available to users in the US, UK, Canada, France, Germany, India, Israel, Italy, Japan, South Korea, the Netherlands, Spain, Switzerland, the US and Canada.
The campaign is intended to help customers get the name they want, and will also have an impact on their health care providers, and the pharmaceutical companies that manufacture them.
How will people know the difference between a generic and a brand-new drug?
People will be able to purchase generic drugs from a pharmacy and get prescriptions.
They will not have to take their medicine from a generic pharmacy and go to the pharmacy to obtain a generic prescription.
For those who do not have a generic supply, they will be given a generic generic medicine by a doctor or nurse who has been trained in the use of Medivacon.
This person will also be able give the medicine to anyone who has a prescription for it.
What are the implications for health care?
For some people, the new Medivaci will be a boon.
As this is a generic version of a generic medicine, patients will be better able to find one that is right for them.
However there is a potential for the brand-name to make it harder for people with pre-existing conditions to access the drug.
This is particularly problematic for patients with severe medical conditions, such as heart failure, stroke, cancer, epilepsy, epilepsy-related epilepsy, or people with a family history of epilepsy, such a family member, or a relative.
Can this drug cause cancer?
According to a new study published in the journal BMC Medicine, this is unlikely to be the case.
The study involved 1,000 people who were randomly assigned to receive Medivas, a brand new drug, or an existing generic drug.
The results showed that, on average, MedivAC users were less likely to develop cancer compared to people who received an existing drug.
In fact, they were also less likely than those who received the brand name to develop serious side effects, such in some cases as blood clots.
Where can I find more information about Medivaca?
This study is part of a wider study that is looking at how people use and use the Medvac, a medical device used by more than 300 million people around the world.
In terms of the study, the researchers looked at how the Mediva is used and used by different people in